We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
- Authors
Ogura, Michinori; Ando, Kiyoshi; Suzuki, Tatsuya; Ishizawa, Kenichi; Oh, Sung Yong; Itoh, Kuniaki; Yamamoto, Kazuhito; Au, Wing Yan; Tien, Hwei‐Fang; Matsuno, Yoshihiro; Terauchi, Takashi; Yamamoto, Keiko; Mori, Masahiko; Tanaka, Yoshinobu; Shimamoto, Takashi; Tobinai, Kensei; Kim, Won Seog
- Abstract
Although initial rituximab-containing chemotherapies achieve high response rates, indolent B-cell non-Hodgkin lymphoma (B- NHL), such as follicular lymphoma ( FL), is still incurable. Therefore, new effective agents with novel mechanisms are anticipated. In this multicentre phase II study, patients with relapsed/refractory indolent B- NHL and mantle cell lymphoma ( MCL) received vorinostat 200 mg twice daily for 14 consecutive days in a 21-d cycle until disease progression or unacceptable toxicity occurred. The primary endpoint was overall response rate ( ORR) in FL patients and safety and tolerability in all patients. Secondary endpoints included progression-free survival ( PFS). Fifty-six eligible patients were enrolled; 50 patients (39 with FL, seven with other B- NHL, and four with MCL) were evaluable for ORR, and 40 patients had received rituximab-containing prior chemotherapeutic regimens. For the 39 patients with FL, the ORR was 49% [95% confidence interval ( CI): 32·4, 65·2] and the median PFS was 20 months (95% CI: 11·2, 29·7). Major toxicities were manageable grade 3/4 thrombocytopenia and neutropenia. Vorinostat offers sustained antitumour activity in patients with relapsed or refractory FL with an acceptable safety profile. Further investigation of vorinostat for clinical efficacy is warranted.
- Subjects
CLINICAL trials; B cells; LYMPHOMAS; DISEASE relapse; DISEASE progression; ANTINEOPLASTIC agents; PATIENTS
- Publication
British Journal of Haematology, 2014, Vol 165, Issue 6, p768
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.12819